Johnson & Johnson Acquires Halda Therapeutics, Gaining Innovative Platform to Transform Cancer Treatment and Advance Next-Generation Oral Therapies Johnson & Johnson today announced the successful completion of its acquisition of Halda…
CRISPR Therapeutics Delivers Comprehensive Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) for Autoimmune Diseases and Blood Cancers CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious…
WHO Global Summit Forges a Bold Vision for the Future of Traditional Medicine The second WHO Global Summit on Traditional Medicine, jointly organized with the Government of India, concluded today in New Delhi,…
Finerenone Receives Approval in Japan for Chronic Heart Failure Treatment Bayer today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved finerenone (Kerendia™), a non-steroidal, selective mineralocorticoid…
Pimicotinib Gains Approval in China as First Systemic Therapy for Tenosynovial Giant Cell Tumor Merck, a leading science and technology company, announced today that following Priority Review, the China National…
FDA Approves Subcutaneous Form of Roche’s Lunsumio VELO™ for Relapsed or Refractory Follicular Lymphoma Roche announced today that the US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio…
Novo Nordisk’s Wegovy® Becomes First Oral GLP-1 Therapy Approved in the U.S. for Weight Management Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the…
EC approves TREMFYA® for pediatric plaque psoriasis — first IL-23 inhibitor for children Johnson & Johnson today announced that the European Commission (EC) has extended the marketing authorisation for TREMFYA® (guselkumab) as…
Cytokinetics Announces FDA Approval of MYQORZO™ for Symptomatic Obstructive HCM in Adults Cytokinetics, Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™, 5 mg, 10 mg,…
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Bolstering Leadership in Rare Diseases, Driving Revenue Growth, and Enhancing Financial Outlook BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin…
WuXi Biologics Earns Top “A” Ratings from CDP for Climate Change and Water Security WuXi Biologics announced that it has been named to the CDP “A” lists for both Climate…
Merck Strikes Deal with U.S. Government to Broaden Access to Medicines and Reduce Costs for Americans Merck, known as MSD outside of the United States and Canada, today announced a…